A detailed history of Pro Share Advisors LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 20,886 shares of CRBU stock, worth $40,936. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,886
Previous 16,541 26.27%
Holding current value
$40,936
Previous $27,000 48.15%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.56 - $2.73 $6,778 - $11,861
4,345 Added 26.27%
20,886 $40,000
Q2 2024

Aug 13, 2024

SELL
$1.62 - $5.05 $7,072 - $22,048
-4,366 Reduced 20.88%
16,541 $27,000
Q1 2024

May 08, 2024

BUY
$4.82 - $8.26 $8,213 - $14,075
1,704 Added 8.87%
20,907 $107,000
Q4 2023

Feb 14, 2024

BUY
$3.58 - $6.25 $13,346 - $23,300
3,728 Added 24.09%
19,203 $110,000
Q3 2023

Nov 13, 2023

BUY
$4.08 - $8.14 $16,756 - $33,430
4,107 Added 36.13%
15,475 $73,000
Q2 2023

Aug 10, 2023

BUY
$4.04 - $5.47 $2,173 - $2,942
538 Added 4.97%
11,368 $48,000
Q1 2023

May 11, 2023

SELL
$4.3 - $7.78 $6,161 - $11,148
-1,433 Reduced 11.69%
10,830 $57,000
Q4 2022

Feb 02, 2023

BUY
$5.57 - $11.01 $5,363 - $10,602
963 Added 8.52%
12,263 $77,000
Q3 2022

Nov 04, 2022

BUY
$5.34 - $12.79 $2,707 - $6,484
507 Added 4.7%
11,300 $119,000
Q2 2022

Aug 01, 2022

SELL
$5.1 - $9.74 $25,362 - $48,437
-4,973 Reduced 31.54%
10,793 $59,000
Q1 2022

May 10, 2022

BUY
$8.42 - $15.32 $24,047 - $43,753
2,856 Added 22.12%
15,766 $145,000
Q4 2021

Feb 08, 2022

BUY
$14.59 - $23.26 $188,356 - $300,286
12,910 New
12,910 $195,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.